Diagnostic Value and Biological Significant of cd71 in Lymphoid Disorders

NCT ID: NCT03720977

Last Updated: 2018-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

139 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-01

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CD71 is expressed on activated B and T cells, macrophages, reticulocytes, erythroid precursors, and malignant tissues. , reflecting the requirement for iron in hemoglobin. , CD71 expression is upregulated on immature proliferating cells and low levels on resting mature lymphocytes. In addition to this general function, CD71 appears to play a costimulatory role in T cell activation and receptor for IgA1 antibodies So it is growth receptor that may help in diagnosis of lymphoid disorder and in differentiation of malignant and benign that will be studied investigate CD71 expression in lymphoid disorders and its diagnostic value ,we from collect data patient and do rotune examination

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Routine investigations for diagnosis:

* CBC.
* Bone marrow aspiration morphology.
* Cytochemistry.
* Flow cytometry immunophenotyping.
* Bone marrow biopsy when indicated.
2. Special investigation is flow cytometry examination of CD71 expression.

sample size calculation ; sample size cases 39 sample size controls 39 total sample size 79 sample will be collected from patient in hospital university ,Data will be analysed by SPSS program

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lyphoid Disorders cd71

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patients wiil be diagnosed lymphoid disorders

Exclusion Criteria

* not present
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Marwa Aboelim Shafeik

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marwa Aboelim Shafeik

Principal investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maged Salah, Prof

Role: STUDY_DIRECTOR

Assiut University .clinical pathologydepartment

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marwa Aboelim

Role: CONTACT

01012636292

Tagreed kamal, dr

Role: CONTACT

01002286687

References

Explore related publications, articles, or registry entries linked to this study.

Zhang Q, Steensma DP, Yang J, Dong T, Wu MX. Uncoupling of CD71 shedding with mitochondrial clearance in reticulocytes in a subset of myelodysplastic syndromes. Leukemia. 2019 Jan;33(1):217-229. doi: 10.1038/s41375-018-0204-z. Epub 2018 Jul 26.

Reference Type BACKGROUND
PMID: 30050123 (View on PubMed)

Salzberger W, Martrus G, Bachmann K, Goebels H, Hess L, Koch M, Langeneckert A, Lunemann S, Oldhafer KJ, Pfeifer C, Poch T, Richert L, Schramm C, Wahib R, Bunders MJ, Altfeld M. Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71. PLoS One. 2018 Jul 20;13(7):e0201170. doi: 10.1371/journal.pone.0201170. eCollection 2018.

Reference Type BACKGROUND
PMID: 30028872 (View on PubMed)

Dunsmore G, Koleva P, Ghobakhloo N, Sutton R, Ambrosio L, Meng X, Hotte N, Nguyen V, Madsen KL, Dieleman LA, Huang V, Elahi S. Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy. J Crohns Colitis. 2019 Feb 1;13(2):230-244. doi: 10.1093/ecco-jcc/jjy147.

Reference Type RESULT
PMID: 30272151 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

diagnostic value of cd71

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

B Cell Responses in COVID-19
NCT06891170 COMPLETED